© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 18, 1541-1548,
September 15, 1999
© 1999 Oxford University Press
Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence
Affiliations of authors: J. P. Costantino, S. Anderson, H. S. Wieand, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh; M. E. Gail, Division of Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; D. Pee, Information Management Services, Inc., Bethesda, MD; C. K. Redmond, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh; J. Benichou, Department of Biostatistics, University of Rouen Medical School, France.
Correspondence to: Joseph P. Costantino, Dr.P.H., 230 McKee Place, Suite 403, Pittsburgh, PA 15213 (e-mail: costan+{at}pitt.edu ).
BACKGROUND: In 1989, Gail and colleagues developed a model for estimating the risk of breast cancer in women participating in a program of annual mammographic screening (designated herein as model 1). A modification of this model to project the absolute risk of developing only invasive breast cancer is referred to herein as model 2. We assessed the validity of both models by employing data from women enrolled in the Breast Cancer Prevention Trial. METHODS: We used data from 5969 white women who were at least 35 years of age and without a history of breast cancer. These women were in the placebo arm of the trial and were screened annually. The average follow-up period was 48.4 months. We compared the observed number of breast cancers with the predicted numbers from the models. RESULTS: In terms of absolute risk, the ratios of total expected to observed numbers of cancers (95% confidence intervals [CIs]) were 0.84 (0.73-0.97) for model 1 and 1.03 (0.88-1.21) for model 2, respectively. Within the age groups of 49 years or less, 50-59 years, and 60 years or more, the ratios of expected to observed numbers of breast cancers (95% CIs) for model 1 were 0.91 (0.73-1.14), 0.96 (0.73-1.28), and 0.66 (0.52-0.86), respectively. Thus, model 1 underestimated breast cancer risk in women more than 59 years of age. For model 2, the risk ratios (95% CIs) were 0.93 (0.72-1.22), 1.13 (0.83-1.55), and 1.05 (0.80-1.41), respectively. Both models exhibited a tendency to overestimate risk for women classified in the higher quintiles of predicted 5-year risk and to underestimate risk for those in the lower quintiles of the same. CONCLUSION: Despite some limitations, these methods provide useful information on breast cancer risk for women who plan to participate in an annual mammographic screening program.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Crandall, A. K. Aragaki, R. T. Chlebowski, A. McTiernan, G. Anderson, S. L. Hendrix, B. B. Cochrane, L. H. Kuller, and J. A. Cauley New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk Arch Intern Med, October 12, 2009; 169(18): 1684 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Gail Value of Adding Single-Nucleotide Polymorphism Genotypes to a Breast Cancer Risk Model J Natl Cancer Inst, July 1, 2009; 101(13): 959 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Amir and O. Freedman Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia J. Clin. Oncol., March 20, 2009; 27(9): 1526 - 1526. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Boughey, L. C. Hartmann, and V. S. Pankratz In Reply J. Clin. Oncol., March 20, 2009; 27(9): 1527 - 1527. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, J. A. Tice, S. Bauer, W. S. Browner, J. Cuzick, E. Ziv, V. Vogel, J. Shepherd, C. Vachon, R. Smith-Bindman, et al. Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk J Natl Cancer Inst, March 18, 2009; 101(6): 384 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Afonso Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know J Am Board Fam Med, January 1, 2009; 22(1): 43 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thomsen and J. M. Kolesar Chemoprevention of breast cancer Am. J. Health Syst. Pharm., December 1, 2008; 65(23): 2221 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Pankratz, L. C. Hartmann, A. C. Degnim, R. A. Vierkant, K. Ghosh, C. M. Vachon, M. H. Frost, S. D. Maloney, C. Reynolds, and J. C. Boughey Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia J. Clin. Oncol., November 20, 2008; 26(33): 5374 - 5379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shen, J. P. Costantino, and J. Qin Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer J Natl Cancer Inst, October 15, 2008; 100(20): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M.G. Taylor, D. P. Ankerst, and R. R. Andridge Validation of Biomarker-Based Risk Prediction Models Clin. Cancer Res., October 1, 2008; 14(19): 5977 - 5983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk J Natl Cancer Inst, July 16, 2008; 100(14): 1037 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grady, J. A. Cauley, M. J. Geiger, M. Kornitzer, L. Mosca, P. Collins, N. K. Wenger, J. Song, J. Mershon, E. Barrett-Connor, et al. Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk J Natl Cancer Inst, June 18, 2008; 100(12): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Pories, D. Zurakowski, R. Roy, C. C. Lamb, S. Raza, A. Exarhopoulos, R. G. Scheib, S. Schumer, C. Lenahan, V. Borges, et al. Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Euhus, D. Bu, S. Milchgrub, X.-J. Xie, A. Bian, A. M. Leitch, and C. M. Lewis DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1051 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Tice, S. R. Cummings, R. Smith-Bindman, L. Ichikawa, W. E. Barlow, and K. Kerlikowske Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model Ann Intern Med, March 4, 2008; 148(5): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail, J. P. Costantino, D. Pee, M. Bondy, L. Newman, M. Selvan, G. L. Anderson, K. E. Malone, P. A. Marchbanks, W. McCaskill-Stevens, et al. Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women J Natl Cancer Inst, December 5, 2007; 99(23): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail, W. F. Anderson, M. Garcia-Closas, and M. E. Sherman Absolute Risk Models for Subtypes of Breast Cancer J Natl Cancer Inst, November 21, 2007; 99(22): 1657 - 1659. [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, J. Lin, H. B. Grossman, M. Huang, J. Gu, C. J. Etzel, C. I. Amos, C. P. Dinney, and M. R. Spitz Projecting Individualized Probabilities of Developing Bladder Cancer in White Individuals J. Clin. Oncol., November 1, 2007; 25(31): 4974 - 4981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lithgow, A. Nyamathi, D. Elashoff, O. Martinez-Maza, and C. Covington C-reactive Protein in Nipple Aspirate Fluid Associated With Gail Model Factors Biol Res Nurs, October 1, 2007; 9(2): 108 - 116. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Euhus, D. Bu, R. Ashfaq, X.-J. Xie, A. Bian, A. M. Leitch, and C. M. Lewis Atypia and DNA Methylation in Nipple Duct Lavage in Relation to Predicted Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1812 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J Santen, N. F Boyd, R. T Chlebowski, S. Cummings, J. Cuzick, M. Dowsett, D. Easton, J. F Forbes, T. Key, S. E Hankinson, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model Endocr. Relat. Cancer, June 1, 2007; 14(2): 169 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, N. Rotmensz, B. Bonanni, P. Boyle, G. Viale, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, et al. Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy J Natl Cancer Inst, May 2, 2007; 99(9): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Armstrong, E. Moye, S. Williams, J. A. Berlin, and E. E. Reynolds Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians Ann Intern Med, April 3, 2007; 146(7): 516 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, and A. Decensi Tamoxifen: An Enduring Star J Natl Cancer Inst, February 21, 2007; 99(4): 258 - 260. [Full Text] [PDF]
|
|
|
|
|
|
Y. M. Coyle, X.-J. Xie, C. M. Lewis, D. Bu, S. Milchgrub, and D. M. Euhus Role of Physical Activity in Modulating Breast Cancer Risk as Defined by APC and RASSF1A Promoter Hypermethylation in Nonmalignant Breast Tissue Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 192 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Elmore and S. W. Fletcher The Risk of Cancer Risk Prediction: "What Is My Risk of Getting Breast Cancer?" J Natl Cancer Inst, December 6, 2006; 98(23): 1673 - 1675. [Full Text] [PDF]
|
|
|
|
|
|
A. Decarli, S. Calza, G. Masala, C. Specchia, D. Palli, and M. H. Gail Gail Model for Prediction of Absolute Risk of Invasive Breast Cancer: Independent Evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition Cohort J Natl Cancer Inst, December 6, 2006; 98(23): 1686 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Armstrong, D. A. Quistberg, E. Micco, S. Domchek, and C. Guerra Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med, November 13, 2006; 166(20): 2260 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, D. Pee, R. Ayyagari, B. Graubard, C. Schairer, C. Byrne, J. Benichou, and M. H. Gail Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst, September 6, 2006; 98(17): 1215 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lippman, S. R. Cummings, D. P. Disch, J. L. Mershon, S. A. Dowsett, J. A. Cauley, and S. Martino Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk Clin. Cancer Res., September 1, 2006; 12(17): 5242 - 5247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor, L. Mosca, P. Collins, M. J. Geiger, D. Grady, M. Kornitzer, M. A. McNabb, N. K. Wenger, and the Raloxifene Use for The Heart (RUTH) Trial Inve Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., July 13, 2006; 355(2): 125 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Beattie, J. P. Costantino, S. R. Cummings, D. L. Wickerham, V. G. Vogel, M. Dowsett, E. J. Folkerd, W. C. Willett, N. Wolmark, and S. E. Hankinson Endogenous Sex Hormones, Breast Cancer Risk, and Tamoxifen Response: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1) J Natl Cancer Inst, January 18, 2006; 98(2): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, J. P. Costantino, D. L. Wickerham, R. S. Cecchini, W. M. Cronin, A. Robidoux, T. B. Bevers, M. T. Kavanah, J. N. Atkins, R. G. Margolese, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst, November 16, 2005; 97(22): 1652 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, D. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, E. Pukkala, C. F. Lynch, et al. Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma J Natl Cancer Inst, October 5, 2005; 97(19): 1428 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Freedman, D. Seminara, M. H. Gail, P. Hartge, G. A. Colditz, R. Ballard-Barbash, and R. M. Pfeiffer Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application J Natl Cancer Inst, May 18, 2005; 97(10): 715 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Taylor and K. Taguchi Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump Ann. Fam. Med, May 1, 2005; 3(3): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Whiteman and A. C. Green A Risk Prediction Tool for Melanoma? Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 761 - 763. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tice, R. Miike, K. Adduci, N. L. Petrakis, E. King, and M. R. Wrensch Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 324 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Lewis, L. R. Cler, D.-W. Bu, S. Zochbauer-Muller, S. Milchgrub, E. Z. Naftalis, A. M. Leitch, J. D. Minna, and D. M. Euhus Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk Clin. Cancer Res., January 1, 2005; 11(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Newman Breast Cancer in African-American Women Oncologist, January 1, 2005; 10(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, J. Mershon, D. Disch, R. J. Secrest, S. R. Cummings, and For the CORE Investigators Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene J Natl Cancer Inst, December 1, 2004; 96(23): 1751 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Lewis, L. S. Kinsinger, R. P. Harris, and R. J. Schwartz Breast Cancer Risk in Primary Care: Implications for Chemoprevention Arch Intern Med, September 27, 2004; 164(17): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fosket Constructing "High-Risk Women": The Development and Standardization of a Breast Cancer Risk Assessment Tool Science Technology Human Values, July 1, 2004; 29(3): 291 - 313. [Abstract] [PDF]
|
|
|
|
|
|
J. Wang, J. P. Costantino, E. Tan-Chiu, D. L. Wickerham, S. Paik, and N. Wolmark Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer J Natl Cancer Inst, April 21, 2004; 96(8): 616 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Colditz, B. A. Rosner, W. Y. Chen, M. D. Holmes, and S. E. Hankinson Risk Factors for Breast Cancer According to Estrogen and Progesterone Receptor Status J Natl Cancer Inst, February 4, 2004; 96(3): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Amir, D G Evans, A Shenton, F Lalloo, A Moran, C Boggis, M Wilson, and A Howell Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme J. Med. Genet., November 1, 2003; 40(11): 807 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Freedman, B. I. Graubard, S. R. Rao, W. McCaskill-Stevens, R. Ballard-Barbash, and M. H. Gail Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention J Natl Cancer Inst, April 2, 2003; 95(7): 526 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Vogel and S. Lo Preventing Hormone-Dependent Breast Cancer in High-Risk Women J Natl Cancer Inst, January 15, 2003; 95(2): 91 - 93. [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, N. Rotmensz, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, F. Lovison, G. Gucciardo, M. G. Muraca, et al. Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women J Natl Cancer Inst, January 15, 2003; 95(2): 160 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pichert, B. Bolliger, K. Buser, and O. Pagani Evidence-based management options for women at increased breast/ovarian cancer risk Ann. Onc., January 1, 2003; 14(1): 9 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ Clin. Cancer Res., January 1, 2003; 9(1): 495s - 501s. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 2, 2002; 137(1): 59 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Thomas, R. A. Carter, W. H. Bush Jr., R. M. Ray, J. L. Stanford, C. D. Lehman, J. R. Daling, K. Malone, and S. Davis Risk of Subsequent Breast Cancer in Relation to Characteristics of Screening Mammograms from Women Less Than 50 Years of Age Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rhodes Identifying and Counseling Women at Increased Risk for Breast Cancer Mayo Clin. Proc., April 1, 2002; 77(4): 355 - 361. [Abstract] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Breast Cancer Risk Prediction: Should Nipple Aspiration Fluid Cytology Be Incorporated Into Clinical Practice? J Natl Cancer Inst, December 5, 2001; 93(23): 1762 - 1763. [Full Text] [PDF]
|
|
|
|
|
|
R. Day, P. A. Ganz, and J. P. Costantino Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study J Natl Cancer Inst, November 7, 2001; 93(21): 1615 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Dooley, B.-M. Ljung, U. Veronesi, M. Cazzaniga, R. M. Elledge, J. A. O'Shaughnessy, H. M. Kuerer, D. T. Hung, S. A. Khan, R. F. Phillips, et al. Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer J Natl Cancer Inst, November 7, 2001; 93(21): 1624 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Maskarinec, L. Meng, and G. Ursin Ethnic differences in mammographic densities Int. J. Epidemiol., October 1, 2001; 30(5): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Vogel Reducing the Risk of Breast Cancer With Tamoxifen in Women at Increased Risk J. Clin. Oncol., September 15, 2001; 19(90001): 87s - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McTiernan, A. Kuniyuki, Y. Yasui, D. Bowen, W. Burke, J. B. Culver, R. Anderson, and S. Durfy Comparisons of Two Breast Cancer Risk Estimates in Women with a Family History of Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 333 - 338. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Gail and J. P. Costantino Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer J Natl Cancer Inst, March 7, 2001; 93(5): 334 - 335. [Full Text] [PDF]
|
|
|
|
|
|
B. Rockhill, D. Spiegelman, C. Byrne, D. J. Hunter, and G. A. Colditz Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for Chemoprevention J Natl Cancer Inst, March 7, 2001; 93(5): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ravdin, L. A. Siminoff, G. J. Davis, M. B. Mercer, J. Hewlett, N. Gerson, and H. L. Parker Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer J. Clin. Oncol., February 15, 2001; 19(4): 980 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B Claus Risk models in genetic epidemiology Statistical Methods in Medical Research, December 1, 2000; 9(6): 589 - 601. [Abstract] [PDF]
|
|
|
|
|
|
H. J. Smedira Practical Issues in Counseling Healthy Women About Their Breast Cancer Risk and Use of Tamoxifen Citrate Arch Intern Med, November 13, 2000; 160(20): 3034 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian, B. F. Kimler, C. M. Zalles, J. R. Klemp, S. Kamel, S. Zeiger, and M. S. Mayo Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model J Natl Cancer Inst, August 2, 2000; 92(15): 1217 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Armstrong, A. Eisen, and B. Weber Assessing the Risk of Breast Cancer N. Engl. J. Med., February 24, 2000; 342(8): 564 - 571. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail, J. P. Costantino, J. Bryant, R. Croyle, L. Freedman, K. Helzlsouer, and V. Vogel Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1829 - 1846. [Abstract] [Full Text] [PDF]
|
|